Mast cell-expressed membrane protein 1 (MCEMP1) is a type II transmembrane protein predominantly expressed in myeloid lineage immune cells, including lung-resident mast cells and alveolar macrophages. MCEMP1 is a critical factor in allergic and inflammatory lung diseases, with higher expression levels correlating with increased disease severity. However, the molecular mechanisms underlying the role of MCEMP1 in the pathogenesis of lung inflammatory diseases remain unclear.
Chiesi Farmaceutici SpA has synthesized pyridazinyl amino derivatives acting as TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported for be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Senisca Ltd. has been awarded a £571,350 (US$712,000) grant from Innovate UK toward the development of oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF).
In its $2 billion acquisition of Bellus Health Inc., GSK plc is getting camlipixant, which is being developed to treat refractory chronic cough. The selective P2X3 receptor antagonist is currently in phase I and phase III studies. Bellus will be acquired by GSK for $14.75 per share in cash.
With no treatments available to effectively clear mucus, Aer Therapeutics Inc. secured $36 million in a series A financing to advance its novel inhaled small-molecule mucolytic treatment, AER-01, bringing optimism to about 5 million Americans with chronic obstructive pulmonary disease (COPD) who have a high burden of mucus plugs.
Ocean Biomedical Inc. announced it will be targeting its pulmonary fibrosis treatment candidate OCF-203 as a novel therapeutic for fatal pulmonary fibrotic conditions caused by Hermansky-Pudlak syndrome (HPS).
RSS
